Triumeq is a once-daily dolutegravir-based regimen, containing the integrase strand transfer inhibitor (INSTI) dolutegravir and the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine
The activity of lamivudine
against EBOV infection was evaluated in a cell-based ELISA with 1995 isolate EBOV H.
A one-year trial of lamivudine
for chronic hepatitis B.
is the most widely prescribed anti-HBV agent worldwide and was the treatment of choice at the time this phase III trial began.
At 48 weeks, histologic improvement was observed in 72 percent of BARACLUDE patients compared to 62 percent of lamivudine
Combining adefovir with lamivudine
in the presence of lamivudine
resistance seems to slow down the development of lamivudine
resistance compared to switching to adefovir monotherapy .
3) Thus, vaccination could be the therapeutic option with the lowest cost and potentially the greatest benefit, (4) because boosting immune system response to HBV vaccine may offer an advantage to some patients who are infected with the virus and receive lamivudine
treatment for it.
The panel's preferred triple NRTI regimen calls for a combination of abacavir, lamivudine
, and either zidovudine or stavudine.
Serum samples from five HBV DNA-positive (serum load >1000 HBV DNA copies/mL) patients undergoing lamivudine
therapy for more than 6 months were analyzed retrospectively.
shows promise as a useful treatment for hepatitis B, but the length of required therapy and the impact on mortality are still unclear.
Study 863 is a double-blind trial in which investigators randomized 653 treatment naive patients to a regimen of Kaletra plus stavudine (Zerit)and lamivudine
(Epivir) or nelfinavir (Viracept) plus stavudine and lamivudine
Due to similarities between emtricitabine and lamivudine
, ATRIPLA should not be coadministered with drugs containing lamivudine
, including Combivir, Epivir([R]), Epivir-HBV([R]), Epzicom(TM), or Trizivir([R]).
com/research/bhw75w/investigation) has announced the addition of the "Investigation Report on China's Lamivudine
Market, 2010-2019" report to their offering.
1 Zidovudine 300 mg + Lamivudine
150mg + Nevirapine 200 mg.
Overall, 42% of the patients had received lamivudine
(Epivir), 32% had received adefovir (Hepsera), 10% had received tenofovir (Viread), 9% had received telbivudine (Tyzeka), and 7% had received entecavir (Baraclude).